secwatch.observer — SEC 8-K summary
======================================

Issuer:     PERRIGO Co plc (PRGO)
CIK:        0001585364
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001193125-24-111405
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M
------------------------------------------------------------------

- Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.
- Esteve Healthcare signed binding offer; Perrigo has a put option to finalize sale.
- Transaction expected to close in Q3 2024, subject to Works Council consultation and regulatory approvals.
- Sale includes HRA Pharma Rare Diseases business; Perrigo will proceed after French Works Council process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/0001193125-24-111405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/d813932d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-111405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer